TLX: Strong imaging sales, FDA approvals, and late-stage trials drive growth and innovation
The company highlighted strong commercial performance in imaging, recent FDA approvals, and a robust late-stage pipeline in urology and neuro-oncology. Key trials like BiPASS and ProstACT GLOBAL 2 are progressing, with major data readouts expected by early next year.Based on Telix Pharmaceuticals L…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.